MedTrace Logo

Study of OTSGC-A24 Vaccine in Advanced Gastric Cancer

NCT01227772 · Status: UNKNOWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 23

Last updated 2016-06-22

No results posted yet for this study

Summary

Active vaccination with tumor specific antigens and VEGFR1 HLA-A24 epitopes can improve survival of patients with advanced Gastric Cancer.

Conditions

Interventions

BIOLOGICAL

OTSGC-A24

OTSGC-A24 administered at 1 mg in weekly, 2-weekly, and 3-weekly cohorts.

Sponsors & Collaborators

  • Wakayama Medical University

    collaborator OTHER

  • Severance Hospital

    collaborator OTHER

  • National University Hospital, Singapore

    lead OTHER

Principal Investigators

  • Wei Peng Yong, MRCP, MB ChB · National University Hospital, Singapore

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
21 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-11-30
Primary Completion
2016-11-30
Completion
2017-06-30

Countries

  • Japan
  • Singapore
  • South Korea

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01227772 on ClinicalTrials.gov